Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) CEO Richard F. Pops sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $46.72, for a total transaction of $2,336,000.00. Following the transaction, the chief executive officer now directly owns 520,063 shares of the company’s stock, valued at approximately $24,297,343. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday, May 2nd. They now have a $50.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Alkermes Plc from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 16th. They now have a $45.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $49.50.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 5.71% on Friday, hitting $50.88. The stock had a trading volume of 2,464,335 shares. Alkermes Plc has a 1-year low of $26.47 and a 1-year high of $54.25. The stock has a 50-day moving average of $46.26 and a 200-day moving average of $45.63. The company’s market cap is $7.353 billion.

Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.11 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter last year, the company posted $0.40 earnings per share. Alkermes Plc’s revenue was down 20.3% compared to the same quarter last year. Analysts expect that Alkermes Plc will post $0.49 EPS for the current fiscal year.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.